Evidence map›Paper›PMID 22819856›Full record

ArticleMethods (San Diego, Calif.)2012

Anti-idiotypic monobodies for immune response profiling.

Mark A Sullivan, Tim Wentworth, James J Kobie, Ignacio Sanz

Abstract read
In one paragraph

Article in Methods (San Diego, Calif.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Chimeric Protein Switch Biosensors.Advances in biochemical engineering/biotechnology · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mark A SullivanDepartment of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA. mark_sullivan@urmc.rochester.edu
Tim Wentworth
James J Kobie
Ignacio Sanz

Funding

UNIVERSITY OF ROCHESTER'S RESEARCH ASSOCIATE ORGANIZATIONUL1RR024160 · NCRR · UNIVERSITY OF ROCHESTER · PI PEARSON, THOMAS ARTHUR · 2006 to 2011
$38.7M
Translational Research Project Effector and Regulatory B cells in SLEU19AI056390 · NIAID · UNIVERSITY OF ROCHESTER · PI LOONEY, RICHARD JOHN · 2003 to 2013
$8.9M
A Model System for the Study of Human B-cell ToleranceR37AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2010 to 2019
$3.7M
The University of Rochester's Clinical and Translational Science InstituteTL1RR024135 · NCRR · UNIVERSITY OF ROCHESTER · PI PEARSON, THOMAS ARTHUR · 2006 to 2011
$3.7M
Understanding the Generation of HIV Broadly Neutralizing AntibodiesR01AI084808 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2009 to 2013
$3.2M
IMMUNE FUNCTION AND BIODEFENSE IN CHILDREN. ELDERLY AND IMMUNOCOMPROMI-266050029N01AI050029 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2006 to 2006
–
NCRR NIH HHS TL1 RR024135NCRR NIH HHS UL1 RR024160NIAID NIH HHS N01 AI050029NIAID NIH HHS R01 AI084808NIAID NIH HHS R01-AI084808NIAID NIH HHS R37 AI049660NIAID NIH HHS U19 AI056390
6 · The paper itself

Abstract

A major goal in the study of autoimmune disease is the identification of biomarkers of disease to allow early diagnosis and initiation of treatment. The production of autoantibodies is the key feature of most autoimmune disease, so much effort has focused on characterizing the antigens reactive with these antibodies. However, even for the most well understood autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, identification of antigens that detect autoantibodies in all patients have yet to be discovered. We describe a novel strategy for deriving mimotopes to disease-specific serum antibodies by selecting anti-idiotypic monobodies from a large molecular diversity library. Monobodies are derived by partial randomization of two surface exposed loops of a fibronectin domain scaffold in a phage display vector. The phage library is selected for binding to serum antibodies using a subtractive panning strategy. We evaluated this strategy by selecting the monobody library on a pool of serum immunoglobulin derived from a group of rheumatoid arthritis patients and evaluated selected clones for multi-patient reactivity and specificity for rheumatoid arthritis. The use of the fibronectin scaffold to derive stable, easy to produce molecular probes for diagnosis of autoimmune disease could be of significant value in improving diagnostic assays for virtually any disease that exhibits a characteristic immune response.

Indexed as

Cell Surface Display TechniquesAmino Acid SequenceAntibodies, Anti-IdiotypicAntibody SpecificityAntigensArthritis, RheumatoidAutoantibodiesEnzyme-Linked Immunosorbent AssayEpitopesFibronectinsHEK293 CellsHumansImmunoglobulin GMolecular MimicryMolecular Sequence DataPeptide FragmentsAntibodies, Anti-IdiotypicAntigensAutoantibodiesEpitopesFibronectinsImmunoglobulin GPeptide FragmentsPeptide Library

Identifiers

PMID22819856
PMCPMC3491107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.